- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05053789
Efficacy of Different Treatment Regimens With Chitosan-N- Acetylcysteine in Moderate-to-severe Dry Eye Disease
Efficacy of Different Treatment Regimens With Chitosan-N- Acetylcysteine (Lacrimera®) in Moderate-to-severe Dry Eye Disease: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1140
- Vienna Institute for Research in Ocular Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age older than 22 years
- Corneal staining (marked to severe; NEI grading scale >=10)
Exclusion Criteria:
- Usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-A)
- Usage of systemic antibiotic therapy
- Any pathology of the ocular surface except dry eye disease (e.g. corneal scarring, cornea ectasia)
- Ocular surgery within prior 3 months to screening
- Preceding refractive corneal surgery (e.g. LASIK)
- Ocular injury within prior 3 months
- Ocular herpes of eye or eyelid within prior 3 months
- Active ocular infection
- Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months
- Eyelid abnormalities that affect lid function
- Ocular surface abnormality that may compromise corneal integrity
- Pregnancy and nursing women (in women of childbearing age a pregnancy test will be performed before inclusion into the study)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
After enrolment into the study and randomization to the study group (V0) and baseline examinations (V1), patients will receive 1 drop of Lacrimera at the study site and will be instructed to apply one drop of C-NAC into both eyes before bedtime for the following 5 consecutive days and return for a follow-up visit after 7±1 days (V2).
Patients will complete a diary describing symptoms during the day, use of Lacrimera and potential side effects until the next visit.
If the NEI grading is ≤1 OR the OSDI score <20 at the next visit, treatment with Lacrimera will be discontinued and one further physical follow-up appointment will be arranged, which will take place 28±2 days after the last physical visit.
|
A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
|
Active Comparator: Group 2
The study days are conducted in the same way as for the study group.
Patients of the control group will receive preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine) for 4 times a day as control.
|
Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of treatment
Time Frame: 1 month
|
Duration of treatment in days until objectively confirmed recovery (NEI (National Eye Institute) grading ≤1 OR OSDI (Ocular Surface Disease Index) score <20, either 7±1, 14±1, 21±1 or 28±1 days) in the study group compared to the control group.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in BUT (Break Up Time)
Time Frame: 1 month
|
Change in BUT (Break Up Time) at different visits in both groups. Fluorescein Break Up time is measured after instillation of 100 μl fluorescein into the inferior fornix. Using a stopwatch time after the last blink until the first break up of the tear film is recorded. Three consecutive measurements are performed, and the average is calculated. Non-invasive first and averaged BUT is measured three times and averaged afterwards using the Dry eye module build into the corneal tomography device (Sirius, CSO, Italy). |
1 month
|
Change in NI-BUT (Non-invasive Break Up Time)
Time Frame: 1 month
|
Change in NI-BUT (Non-invasive Break Up Time) at different visits in both groups.
The Sirius device is a routinely used device for the detailed assessment of the cornea and the tear film.
NI-BUT is assessed by monitoring placido discs (Sirius, CSO, Italy) projected onto the cornea.
3 consecutive measurements are made in every eye.
|
1 month
|
OSDI (Ocular Surface Disease Index)
Time Frame: 1 month
|
OSDI (Ocular Surface Disease Index) at different visits in both groups.
The OSDI Questionnaire is a standardized questionnaire to evaluate the subjective disease burden caused by dry eye syndrome.
The patients answer up to 12 questions regarding their symptoms.
Thereafter, the OSDI Score is calculated.
|
1 month
|
Flourescein staining / Lissamin green staining grading using the NEI Score (National Eye Institute)
Time Frame: 1 month
|
Lissamin green staining at different visits in both groups using the NEI Score.
Fluorescein and Lissamin green dye will be used to examine the anterior surface of the human eye.
Anterior Segment Photography will be used to document the findings, which are graded using the National Eye Institute (NEI) grading scale.
|
1 month
|
Change in number of MMP-positive eyes (Matrix Metallopeptidase 9)
Time Frame: 1 month
|
Change in number of MMP-positive eyes in both groups (Matrix Metallopeptidase 9).
MMP-9 is an inflammatory marker of the ocular surface.
InflammaDry® allows to indicate elevated levels of MMP-9 in tear fluid by microfiltration technology.
Patients will be instructed to look upward, and the lower eye lid will be pulled downward gently.
Samples will be collected by dabbing a tear sample collector in 6-8 locations on the palpebral conjunctiva.
The test is routinely performed in our dry eye unit.
|
1 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Lacrimera Efficacy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eye Diseases
-
University of Alabama at BirminghamPfizerCompletedVision | Eye Disease | Eye CareUnited States
-
TBF Genie TissulaireCompletedEnucleated; Eye | Eye CancerFrance
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
National Eye Institute (NEI)RecruitingInherited Eye DiseaseUnited States, United Kingdom, China, Pakistan, Philippines, Ukraine, India, Italy
-
National Eye Institute (NEI)Recruiting
-
National Eye Institute (NEI)RecruitingGenetic Eye DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
OptovueCompletedNo Eye DiseaseUnited States, United Kingdom
-
National Eye Institute (NEI)CompletedHereditary Eye DiseaseUnited States
Clinical Trials on Lacrimera
-
Vienna Institute for Research in Ocular SurgeryTerminatedEye DiseasesAustria
-
Vienna Institute for Research in Ocular SurgeryTerminated
-
Vienna Institute for Research in Ocular SurgeryCompleted